patient-derived CD22-specific CAR T-cells expressing EGFRt

Patient-derived CD22-specific CAR T-cells expressing EGFRt is an autologous, patient-derived chimeric antigen receptor (CAR) T-cell therapy developed by Seattle Children's Hospital. It is designed to target the CD22 antigen, a protein commonly expressed on the surface of B-cell malignancies such as acute lymphoblastic leukemia (ALL) and lymphoma. The therapy involves genetically modifying a patient's own T cells to express a CAR specific to CD22, enabling them to recognize and eliminate cancer cells. The construct also includes a truncated epidermal growth factor receptor (EGFRt) tag, which functions as a tracking marker and a potential safety switch for in vivo depletion of the CAR T-cells if necessary. This investigational agent is primarily being evaluated in the PLAT-04 clinical trial for pediatric and young adult patients with relapsed or refractory CD22-positive disease, particularly those who have experienced antigen escape following CD19-targeted therapies.

Other names

CD22-specific CAR T-cellsCD-22-specific CAR T-cellsCD 22-specific CAR T-cellsCD22 CAR-T cellsCD-22 CAR-T cellsCD 22 CAR-T cellsautologous CD22-specific CAR T-cellsCD22-CAR T cell immunotherapyCD-22-CAR T cell immunotherapyCD 22-CAR T cell immunotherapy